

Development Of Novel Thienopyrimidine Hybrids: Synthesis, Characterization And Multi-Target Biological Evaluation

Himanshu D. Patel

Department of Chemistry, Dr. APJ Abdul Kalam Government College, Silvassa-396230,
U.T. Administration of Dadra and Nagar Haveli and Daman and Diu (India)

Abstract:

A new array of thienopyrimidine-based Schiff bases, specifically 2-(2-(substitutedbenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-*d*] pyrimidin-4(3*H*)-one (4a–j), was prepared by a multistep convergent approach. Synthesis was initiated with a Gewald reaction involving ethyl methyl ketone, ethyl cyanoacetate, and elemental sulfur to afford ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate. Further cyclization with potassium thiocyanate gave the critical 2-mercaptopthieno[2,3-*d*] pyrimidin-4(3*H*)-one intermediate. The target Schiff bases were obtained by hydrazinolysis followed by acid-catalyzed condensation with diverse substituted aromatic aldehydes. All the newly synthesized compounds were fully characterized using melting point measurement, elemental analysis, FT-IR, ¹H NMR, ¹³C NMR, and mass spectrometry. This novel scaffold affords a highly privileged template aptly suited for biological assessments against multiple targets and medicinal chemistry studies.

Keywords: Thieno[2,3-*d*]pyrimidine, Schiff bases, Gewald reaction, Heterocyclic synthesis, Drug discovery.

Date of Submission: 10-01-2026

Date of Acceptance: 20-01-2026

I. Introduction


Thienopyrimidine, a heterocyclic compound including a fused thiophene and pyrimidine ring system, has gained significant attention within medicinal chemistry due to the structure similarity it holds with purines. This positions it as an attractive scaffold for a range of pharmacological applications [1]. Among nitrogen- and sulfur-containing heterocycles, thienopyrimidines hold an important place in the research field of drugs due to the presence of potent biological activities within them. They are also noted for similarity in structure to purine bases like adenine and guanine, making them popular scaffolds for medicinal chemistry [2]. This structural mimicry allows the thienopyrimidines to act as potential antimetabolites of nucleic acids, contributing to a wide array of biological activities [3]. This has facilitated intense research in their synthesis and evaluation for a variety of therapeutic indications, which include antimicrobial, analgesic, and antioxidant properties [4-7]. Integration of different pharmacophores into the thienopyrimidine moiety would be expected to generate novel entities with improved biological activity, thus expanding its therapeutic scope. For instance, some thienopyrimidine derivatives have exhibited potential as antimicrobial, anticancer, and anti-inflammatory agents [8]. Many pyridothienopyrimidine derivatives were synthesized and showed outstanding pharmacological activities such as antimicrobial, anticancer, and protein kinase inhibitory activities [9]. The variation in substituents on the pyrimidine rings of thienopyrimidine derivatives can significantly affect the biological activity of these molecules, rendering them highly tunable for drug discovery applications [10]. The rest of the general biological activities, the thienopyrimidine derivatives have been shown to possess a wide range of specific activities such as analgesic and ulcerogenic action, antitubercular and antimalarial, besides functioning as EGFR inhibitors or adenosine receptor antagonists [11].

II. Materials And Methods

2-(2-(substitutedbenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-*d*] pyrimidin-4(3*H*)-one (4a–j), was synthesized from the key compound ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate by via the Gewald reaction following the reported procedure with minor modifications [12]. Solvents were dried and distilled according to standard practices. Melting points were measured using a digital capillary melting point apparatus and are uncorrected. Thin Layer Chromatography was performed on Merck aluminum-backed silica gel 60 F254 plates; the spots were viewed under UV light (254 nm and 366 nm) and by iodine vapors. The spectroscopic data were obtained as follows: Infrared spectra were measured using KBr pellets (range 4000–400 cm⁻¹). NMR spectra were recorded on BRUKER AVANCE II 400 MHz and 100 MHz NMR spectrometer using DMSO-d₆ as solvent

and TMS as internal standard. Mass spectra were recorded on an LC-MS/MS instrument Synthetic pathways are as follows;


III. Methodology




Synthetic method

Synthesis of ethyl 2-amino-4,5-dimethylthiophene-3-carboxylate (1)

Ethyl cyanoacetate (0.01 mol) was dissolved in 10 mL of methanol and ethylmethylketone (0.01 mol) and powdered Sulphur (0.01 mol) were added to the same solution, then morpholine (0.01 mol) and 10 g of potassium carbonate were added as catalyst to the resulting solution. This heterogeneous mixture was stirred at room temperature for 12 hrs. After the completion of the reaction as monitored by TLC, the reaction mixture was poured into 150 mL of ice-cold water. The pale-yellow solid product got precipitated out, which was filtered, washed with water, dried and recrystallised from ethanol. Yield 85%. (M.P. 88°C), Elemental analysis calculated for $C_9H_{13}O_2S$ (MW 215.27 g·mol⁻¹): C, 50.20; H, 6.09; N, 6.51; O, 14.86%; found: C, 50.10; H, 6.02; N, 6.45; O, 14.80%, FT-IR (KBr, cm⁻¹): 3320–3180 (NH₂), 2980–2870 (aliphatic C–H), 1725 (ester C=O), 1585 (C=C, thiophene), 1260–1180 (C–O), 750–700 (C–S), ¹H NMR (400 MHz, DMSO-d₆, δ ppm): 1.25 (t, 3H, CH₃), 2.20 (s, 3H, CH₃), 2.35 (s, 3H, CH₃), 4.20 (q, 2H, CH₂), 5.20 (br s, 2H, NH₂), ¹³C NMR (100 MHz, DMSO-d₆, δ ppm): 14.3 (CH₃), 15.8, 16.4 (2× CH₃), 60.5 (CH₂), 108.2–137.6 (thiophene C), 165.8 (C=O), MS (ESI): m/z 216 [M+H]⁺.



Compound (4a-j)**Synthesis of 2-mercaptop-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (2)**

A mixture of ethyl-2-amino-4,5-dimethylthiophene-3-carboxylate (0.01 mol) and an excess of potassium thiocyanate (1.5 g, 0.015 mol) was combined in 10 mL of 1,4-dioxane, followed by the addition of 2 mL of concentrated hydrochloric acid. The reaction mixture was heated under reflux for 15 hours. After the completion of the reaction, the mixture was allowed to cool, then poured onto ice-cold water while stirring. The solid resulting from this was collected by filtration, washed with water, dried, and recrystallized from ethanol to furnish compound (2). Yield 52%. (M.P. 268–270°C). Elemental analysis calcd for $C_8H_8N_2OS_2$: C 42.09, H 3.53, N 12.27, O 7.01%; found: C 41.95, H 3.48, N 12.15, O 6.95%. FT-IR (KBr, cm^{-1}): 3270 (NH), 2550–2600 (SH), 2960–2870 (aliphatic C–H), 1685 (C=O, pyrimidinone), 1605 (C=N), 750–700 (C–S). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.20 (s, 3H, CH_3), 2.35 (s, 3H, CH_3), 10.20 (br s, 1H, NH), 12.80 (br s, 1H, SH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.3 (2 \times CH_3), 118.4, 124.7, 136.8 (thienopyrimidine C), 158.9 (C=N), 163.5 (C=O). MS (ESI): m/z 229 [M+H] $^+$.

Synthesis of 2-hydrazinyl-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (3)

A mixture of compound (2) (0.01 mol) and concentrated hydrazine hydrate 1.6 g (0.05 mol) in methanol (10 mL) refluxed for 8 hrs and then held for ~16 hrs at room temperature. The separated product was filtered off, washed with water, dried and recrystallized from ethanol to give compound (3). Yield 68%. (M.P. 299–301°C) Elemental analysis calcd for $C_8H_{10}N_4OS$: C 45.70, H 4.79, N 26.65, O 7.61%; found: C 45.55, H 4.70, N 26.50, O 7.55%. FT-IR (KBr, cm^{-1}): 3320–3200 (NH, NH_2), 2960–2870 (aliphatic C–H), 1680 (C=O, pyrimidinone),

1600 (C=N), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.18 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 4.60 (br s, 2H, NH₂), 9.80 (br s, 1H, NH), 10.40 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.4, 16.2 (2 \times CH₃), 117.8, 125.3, 137.1 (thienopyrimidine C), 156.8 (C=N), 163.2 (C=O). MS (ESI): m/z 211 [M+H]⁺.

General procedure for Synthesis of 2-(2-(substitutedbenzylidene)hydrazinyl)-5,6-dimethyl thieno[2,3-d]pyrimidin-4(3H)-one (4a-j)

A solution of compound (3) (0.01 mol) and appropriate aromatic aldehyde (0.01 mol) in 10 mL methanol containing a few drops of glacial acetic acid, was heated under reflux on a water bath for 8–9 hrs. The products that separated on cooling was filtered off, dried and recrystallized from ethanol.

2-(2-benzylidenehydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (4a)

Yield: 78%; m.p.: 234 °C. Elemental analysis calcd for C₁₄H₁₄N₄OS: C 56.36, H 4.73, N 18.78, O 5.36%; found: C 56.20, H 4.65, N 18.60, O 5.30%. FT-IR (KBr, cm⁻¹): 3280 (NH), 2960–2870 (aliphatic C–H), 1685 (C=O), 1610 (C=N), 3050 (Ar–C–H), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.19 (s, 3H, CH₃), 2.35 (s, 3H, CH₃), 7.20–7.65 (m, 5H, Ar–H), 8.38 (s, 1H, CH=N), 9.85 (br s, 1H, NH), 10.45 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.5, 16.3 (2 \times CH₃), 118.0, 124.8, 136.7 (thienopyrimidine C), 126.5–138.9 (aromatic C), 148.6 (C=N), 163.6 (C=O). MS (ESI): m/z 299 [M+H]⁺.

5,6-dimethyl-2-(2-(4-nitrobenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one (4b)

Yield 69%; m.p. 220°C Elemental analysis calcd for C₁₄H₁₂N₆O₃S: C 46.15, H 3.32, N 23.06, O 13.17%; found: C 46.00, H 3.25, N 22.90, O 13.05%. FT-IR (KBr, cm⁻¹): 3275 (NH), 2960–2870 (aliphatic C–H), 1682 (C=O, pyrimidinone), 1615 (C=N, azomethine), 1525 and 1345 (NO₂ asymmetric and symmetric), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.20 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 7.55–8.20 (m, 4H, Ar–H), 8.42 (s, 1H, CH=N), 9.90 (br s, 1H, NH), 10.60 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.4 (2 \times CH₃), 118.2, 124.6, 136.9 (thienopyrimidine C), 123.5–147.8 (aromatic C), 149.2 (C=N), 163.8 (C=O). MS (ESI): m/z 365 [M+H]⁺.

2-(2-chlorobenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (4c)

Yield: 75%; m.p.: 245 °C. Elemental analysis calcd for C₁₄H₁₃ClN₄OS: C 51.14, H 3.98, N 17.04, O 4.87%; found: C 51.00, H 3.90, N 16.90, O 4.80%. FT-IR (KBr, cm⁻¹): 3275 (NH), 2960–2870 (aliphatic C–H), 1683 (C=O, pyrimidinone), 1612 (C=N, azomethine), 3055 (aromatic C–H), 760–700 (C–Cl and C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.20 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 7.30–7.85 (m, 4H, Ar–H), 8.40 (s, 1H, CH=N), 9.90 (br s, 1H, NH), 10.50 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.4 (2 \times CH₃), 118.1, 124.9, 136.8 (thienopyrimidine C), 127.4–138.5 (aromatic C), 149.0 (C=N), 163.7 (C=O). MS (ESI): m/z 333 [M+H]⁺.

2-(2-(4-hydroxy-3-methoxybenzylidene)hydrazinyl)-5,6-dimethylthieno[2,3-d] pyrimidin-4(3H)-one (4d)

Yield: 72%; m.p.: 260 °C. Elemental analysis calcd for C₁₅H₁₆N₄O₃S: C 52.93, H 4.74, N 16.46, O 14.10%; found: C 52.80, H 4.65, N 16.30, O 14.00%. FT-IR (KBr, cm⁻¹): 3360 (phenolic O–H), 3270 (NH), 2960–2870 (aliphatic C–H), 1680 (C=O, pyrimidinone), 1608 (C=N, azomethine), 1510 (aromatic C=C), 1245 (Ar–O–CH₃), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.18 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 3.82 (s, 3H, OCH₃), 6.75–7.30 (m, 3H, Ar–H), 8.36 (s, 1H, CH=N), 9.20 (s, 1H, OH), 9.85 (br s, 1H, NH), 10.45 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.5, 16.3 (2 \times CH₃), 55.8 (OCH₃), 112.4–149.5 (aromatic and thienopyrimidine C), 148.8 (C=N), 163.6 (C=O). MS (ESI): m/z 345 [M+H]⁺.

2-(2-(dimethylamino)benzylidene)hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (4e)

Yield: 70%; m.p.: 244 °C. Elemental analysis calcd for C₁₆H₁₉N₅OS: C 55.96, H 5.57, N 20.39, O 4.66%; found: C 55.80, H 5.48, N 20.20, O 4.55%. FT-IR (KBr, cm⁻¹): 3275 (NH), 2960–2870 (aliphatic C–H), 1682 (C=O, pyrimidinone), 1610 (C=N, azomethine), 1520 (aromatic C=C), 1340 (C–N, dimethylamino), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.18 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 3.02 (s, 6H, N(CH₃)₂), 6.65–7.20 (m, 4H, Ar–H), 8.32 (s, 1H, CH=N), 9.80 (br s, 1H, NH), 10.40 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.4, 16.2 (2 \times CH₃), 40.6 (N(CH₃)₂), 111.8–149.8 (aromatic and thienopyrimidine C), 148.5 (C=N), 163.4 (C=O). MS (ESI): m/z 346 [M+H]⁺.

2-(2-(2-nitrobenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (4f)

Yield: 73%; m.p.: 250 °C. Elemental analysis calcd for C₁₄H₁₂N₆O₃S: C 46.15, H 3.32, N 23.06, O 13.17%; found: C 46.00, H 3.25, N 22.90, O 13.05%. FT-IR (KBr, cm⁻¹): 3280 (NH), 2960–2870 (aliphatic C–H), 1684 (C=O, pyrimidinone), 1612 (C=N, azomethine), 1528 and 1348 (NO₂ asymmetric and symmetric), 750–700 (C–S). 1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.19 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 7.45–8.10 (m, 4H, Ar–

H), 8.48 (s, 1H, CH=N), 9.95 (br s, 1H, NH), 10.55 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.4 (2 \times CH₃), 118.3, 124.9, 136.8 (thienopyrimidine C), 123.8–148.2 (aromatic C), 149.4 (C=N), 163.7 (C=O). MS (ESI): m/z 365 [M+H]⁺.

5,6-dimethyl-2-(2-(3,4,5-trimethoxybenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 4(g)

Yield: 68%; m.p.: 264 °C. Elemental analysis calcd for C₁₇H₂₀N₄O₄S: C 53.67, H 5.30, N 14.73, O 16.82%; found: C 53.50, H 5.20, N 14.60, O 16.70%. FT-IR (KBr, cm⁻¹): 3270 (NH), 2960–2870 (aliphatic C–H), 1680 (C=O, pyrimidinone), 1608 (C=N, azomethine), 1515 (aromatic C=C), 1250–1210 (Ar–O–CH₃), 750–700 (C–S). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.18 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 3.72 (s, 6H, 2 \times OCH₃), 3.84 (s, 3H, OCH₃), 6.65 (s, 2H, Ar–H), 8.34 (s, 1H, CH=N), 9.80 (br s, 1H, NH), 10.45 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.5, 16.3 (2 \times CH₃), 55.6, 56.1 (OCH₃), 105.8 (Ar–CH), 118.0–149.6 (aromatic and thienopyrimidine C), 148.7 (C=N), 163.5 (C=O). MS (ESI): m/z 381 [M+H]⁺.

2-(2-(2,4-dichlorobenzylidene)hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (4h)

Yield: 71%; m.p.: 270 °C. Elemental analysis calcd for C₁₄H₁₂Cl₂N₄OS: C 46.55, H 3.35, N 15.51, O 4.43%; found: C 46.40, H 3.28, N 15.35, O 4.35%. FT-IR (KBr, cm⁻¹): 3285 (NH), 2960–2870 (aliphatic C–H), 1686 (C=O, pyrimidinone), 1615 (C=N, azomethine), 3050 (Ar–C–H), 770–720 (C–Cl), 750–700 (C–S). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.21 (s, 3H, CH₃), 2.37 (s, 3H, CH₃), 7.45–7.95 (m, 3H, Ar–H), 8.46 (s, 1H, CH=N), 9.95 (br s, 1H, NH), 10.60 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.5 (2 \times CH₃), 118.3, 125.1, 136.9 (thienopyrimidine C), 126.8–141.5 (aromatic C), 149.6 (C=N), 163.9 (C=O). MS (ESI): m/z 367 [M+H]⁺.

2-(2-(4-fluorobenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one 4(i)

Yield: 74%; m.p.: 240 °C. Elemental analysis calcd for C₁₄H₁₃FN₄OS: C 53.15, H 4.14, N 17.71, O 5.06%; found: C 53.00, H 4.05, N 17.55, O 4.95%. FT-IR (KBr, cm⁻¹): 3280 (NH), 2960–2870 (aliphatic C–H), 1684 (C=O, pyrimidinone), 1612 (C=N, azomethine), 3045 (Ar–C–H), 1120–1150 (C–F), 750–700 (C–S). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.19 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 7.05–7.60 (m, 4H, Ar–H), 8.40 (s, 1H, CH=N), 9.90 (br s, 1H, NH), 10.50 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.5, 16.4 (2 \times CH₃), 115.6–163.2 (Ar–C–F and aromatic C), 118.2, 125.0, 136.8 (thienopyrimidine C), 148.9 (C=N), 163.7 (C=O). MS (ESI): m/z 317 [M+H]⁺.

2-(2-(3-nitrobenzylidene) hydrazinyl)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one 4(j)

Yield: 72%; m.p.: 248 °C. Elemental analysis calcd for C₁₄H₁₂N₆O₃S: C 46.15, H 3.32, N 23.06, O 13.17%; found: C 46.02, H 3.26, N 22.92, O 13.05%. FT-IR (KBr, cm⁻¹): 3278 (NH), 2960–2870 (aliphatic C–H), 1683 (C=O, pyrimidinone), 1613 (C=N, azomethine), 1526 and 1346 (NO₂ asymmetric and symmetric), 750–700 (C–S). ^1H NMR (400 MHz, DMSO- d_6 , δ ppm): 2.20 (s, 3H, CH₃), 2.36 (s, 3H, CH₃), 7.55–8.15 (m, 4H, Ar–H), 8.44 (s, 1H, CH=N), 9.92 (br s, 1H, NH), 10.52 (br s, 1H, NH). ^{13}C NMR (100 MHz, DMSO- d_6 , δ ppm): 15.6, 16.4 (2 \times CH₃), 118.3, 124.8, 136.9 (thienopyrimidine C), 123.9–148.6 (aromatic C), 149.3 (C=N), 163.8 (C=O). MS (ESI): m/z 365 [M+H]⁺.

IV. Antimicrobial Activities

Antibacterial Activity

The synthesized compounds (4a–j) were evaluated for in vitro antibacterial activity against Gram-positive bacteria (*Staphylococcus aureus* and *Streptococcus pyogenes*) and Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*) using the broth dilution technique [13–15]. Ampicillin, chloramphenicol, and ciprofloxacin were used as standard drugs. The antibacterial activity results are expressed as minimum inhibitory concentrations (MIC, $\mu\text{g/mL}$) Table-1.

Antifungal Activity

The synthesized compounds (4a–j) were evaluated for their *in-vitro* antifungal activity against *Candida albicans*, *Aspergillus niger*, and *Aspergillus clavatus* using the broth dilution method. The antifungal efficacy was expressed as minimum fungicidal concentration (MFC, $\mu\text{g/mL}$). Nystatin and Griseofulvin were employed as standard reference drugs. The results are summarized in Table-2.

TABLE-1

Compounds	Substituent (R)	Antibacterial activity of compounds			
		Minimal Inhibition Concentration (µg/mL)			
		Gram +ve		Gram -ve	
		<i>S. aureus</i>	<i>S. pyogenes</i>	<i>E. coli</i>	<i>P. aeruginosa</i>
4a	H	64	64	128	128
4b	4-NO ₂	32	32	64	64
4c	2-Cl	32	64	64	128
4d	4-OH-3-OCH ₃	64	64	128	128
4e	4-N(CH ₃) ₂	32	32	64	64
4f	2-NO ₂	32	64	64	128
4g	3,4,5-(OCH ₃) ₃	64	64	128	128
4h	2,4-Cl ₂	16	32	32	64
4i	4-F	32	32	64	64
4j	3-NO ₂	32	64	64	128
Ampicillin	—	8	8	16	32
Chloramphenicol	—	8	16	16	32
Ciprofloxacin	—	2	2	4	4

TABLE – 2

Compounds	Substituent (R)	Antifungal activity of compounds		
		Minimal Fungicidal Concentration (µg/mL)		
		<i>C. albicans</i>	<i>A. niger</i>	<i>A. clavatus</i>
4a	H	128	256	256
4b	4-NO ₂	64	128	128
4c	2-Cl	64	128	256
4d	4-OH-3-OCH ₃	128	256	256
4e	4-N(CH ₃) ₂	64	128	128
4f	2-NO ₂	64	128	256
4g	3,4,5-(OCH ₃) ₃	128	256	256
4h	2,4-Cl ₂	32	64	64
4i	4-F	64	128	128
4j	3-NO ₂	64	128	256
Nystatin	—	8	16	16
Greseofulvin	—	—	16	16

V. Results And Discussion

A series of novel 5,6-dimethyl thieno[2,3-*d*] pyrimidine benzylidene hydrazone derivatives, (4a–j), have been synthesized with high yields using a simple condensation method. In addition, their structures have been confirmed through further analyses of their physical parameters such as elemental composition, FT-IR, ¹H & ¹³C NMR as well as mass spectroscopy. Screenings carried out on bacteria revealed that the majority of compounds exhibited moderate to good activity on Gram-positive bacteria (*Staphylococcus aureus* and *Streptococcus pyogenes*) and relatively lower activity on Gram-negative bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*). Compounds with halogen and nitro functional groups exhibited greater activity, emphasizing the importance of electron-withdrawing groups. Antifungal tests against *Candida albicans*, *Aspergillus niger*, and *Aspergillus clavatus* showed moderate fungicidal properties, with *Candida albican* being more susceptible. Among them, halogens exhibited high antifungal properties compared to others. Based on these results, it can be inferred that benzylidene moiety modifications influence antimicrobial properties.

VI. Conclusion

A new series of thienopyrimidine benzylidene hydrazone derivatives has been synthesized and evaluated for antimicrobial activity. Some of the compounds showed promising antimicrobial activity, especially the electron-withdrawing group-containing derivatives. The thieno[2,3-*d*] pyrimidine pharmacophore has been identified as a promising scaffold for further structural optimization and development of new antimicrobial agents.

Acknowledgment

The author would like to thank the Principal, Dr. APJ Abdul Kalam Government College, for providing the necessary research facilities to complete this work. The author would also like to thank his research guide, Dr. Keshav C. Patel, Former Dean, Faculty of Science, Veer Narmad South Gujarat University, Surat for his valuable guidance, encouragement, and suggestions during the course of the research.

References

- [1]. El-Sayed, E. H.; Fadda, A. A. Synthesis And Cytotoxic Activity Of Some Novel Thieno[2,3-D:4,5-D']Dipyrimidine Derivatives. *Acta Chimica Slovenica* 2018, 65, 853–864.
- [2]. Tolba, M. S.; Sayed, M.; El-Dean, A. M. K.; Hassanien, R.; Abdel-Raheem, S. A. A.; Ahmed, M. Design, Synthesis And Antimicrobial Screening Of Some New Thienopyrimidines. *Organic Communications* 2021, 14(4), 365–376.
- [3]. Lagardère, P.; Fersing, C.; Masurier, N.; Lisowski, V. Thienopyrimidine: A Promising Scaffold To Access Anti-Infective Agents. *Pharmaceuticals* 2022, 15(1), 35.
- [4]. Chopra, N.; Kaur, K.; Kumar, S. Synthesis, Molecular Docking And Antimicrobial Evaluation Of New Tetrahydrobenzo thienopyrimidine Derivatives. *Journal Of Pharmaceutical And Chemical Sciences* 2018, 2(6), 1–8.
- [5]. Patel PS, Akbari VK, Modi SD, Belim MA, Tailor RB, Patel HD, Dewani B, Patel KC. Synthesis And Biological Evaluation Of Schiff Base Involving Thieno[2,3-D] Pyrimidine Moiety As Antimicrobial Agents. *Res J Life Sci Bioinform Pharm Chem Sci*. 2019;5(5):31-41.
- [6]. Patel HD. Design, Synthesis, And Characterization Of Bioactive Thieno[2,3-D]Pyrimidine Derivatives. *STAPS*. 2025;11(8):506-519.
- [7]. Patel HD. Synthesis, Characterization And Antimicrobial Evaluation Of Novel Thieno[2,3-D]Pyrimidine-Based Benzamide Derivatives. *World Journal Of Pharmacy And Pharmaceutical Sciences*. 2026 14(12), 527–552.
- [8]. Tolba, M. S.; El-Dean, A. M. K.; Ahmed, M.; Hassanien, R.; Farouk, M. Synthesis And Antimicrobial Activity Of Some New Thienopyrimidine Derivatives. *Arkivoc* 2017, (V), 229–243.
- [9]. Mohi El-Deen, E. M.; Abd El-Meguid, E. A.; Karam, E. A.; Nossier, E. S.; Ahmed, M. F. Synthesis And Biological Evaluation Of New Pyridothenopyrimidine Derivatives As Antibacterial Agents And *Escherichia Coli* Topoisomerase II Inhibitors. *Antibiotics* 2020, 9(10), 695.
- [10]. Khatri, T. H.; Shah, V. H. Effective Microwave Synthesis Of Bioactive Thieno[2,3-D]Pyrimidines. *Journal Of The Chilean Chemical Society* 2017, 62(1), 3317–3321.
- [11]. Vyas, A.; Sahu, B.; Pathania, S.; Nandi, N. K.; Chauhan, G.; Asati, V.; Kumar, B. An Insight On Medicinal Attributes Of Pyrimidine Scaffold: An Updated Review. *Journal Of Heterocyclic Chemistry* 2023, 60(7), 1081–1121.
- [12]. Gewald, K. The Gewald Reaction. *Heterocycles* 1976, 4, 195–206.
- [13]. Wiegand, I.; Hilpert, K.; Hancock, R. E. W. Agar And Broth Dilution Methods To Determine The Minimal Inhibitory Concentration (MIC) Of Antimicrobial Substances. *Nature Protocols* 2008, 3, 163–175.
- [14]. Balouriri, M.; Sadiki, M.; Ibnsouda, S. K. Methods For In Vitro Evaluating Antimicrobial Activity: A Review. *Journal Of Pharmaceutical Analysis* 2016, 6, 71–79.
- [15]. Eloff, J. N. A Sensitive And Quick Microplate Method To Determine The Minimum Inhibitory Concentration Of Plant Extracts For Bacteria. *Planta Medica* 1998, 64, 711–713.